Biomarker IDs cancer patients most likely to respond to EGFR inhibitors

A team of scientists at A*STAR's Institute of Molecular and Cell Biology say they've identified a particular biomarker which can be used to identify how patients will likely respond to EGFR inhibitors. They noted that cancer cells with elevated levels of PRL-3 are more rapidly destroyed by EGFR inhibitors, making them prime candidates for therapy. Release

Suggested Articles

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.

Cybernet Manufacturing, maker of medical-grade computer monitors, has unveiled a new, large touchscreen designed to protect against infections.

A startup has raised $12 million to fund its real-time system for monitoring patients undergoing dialysis at home and calling in complications.